United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Florida Financial Advisors LLC

Florida Financial Advisors LLC increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 822 shares of the biotechnology company’s stock after acquiring an additional 48 shares during the period. Florida Financial Advisors LLC’s holdings in United Therapeutics were worth $290,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of UTHR. Wealthfront Advisers LLC increased its holdings in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. increased its holdings in United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after buying an additional 32,213 shares in the last quarter. Geode Capital Management LLC raised its position in shares of United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC boosted its stake in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock valued at $210,869,000 after acquiring an additional 30,931 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 1.0 %

UTHR opened at $316.73 on Wednesday. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The firm has a market capitalization of $14.22 billion, a PE ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. The firm’s 50-day moving average price is $343.28 and its 200 day moving average price is $356.63.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the previous year, the firm posted $4.36 EPS. As a group, analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,755 shares of company stock worth $29,792,021 in the last three months. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.